Carma Ayala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carma Ayala has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Jing Fang
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
3 shared publications- Zefeng Zhang
Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia
2 shared publications Cecily Luncheon
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
1 shared publicationDiane Dunet
1 shared publicationFleetwood Loustalot
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC
1 shared publicationGuijing Wang
1 shared publication
Latest Publications
- 25 May 2018
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 67 (20) , 575-578
Use of Outpatient Rehabilitation Among Adult Stroke Survivors — 20 States and the District of Columbia, 2013, and Four States, 2015
In 2013, approximately 31% of stroke survivors reported participation in outpatient rehabilitation for stroke after hospitalization in 20 states and the District of Columbia.
- 25 May 2018
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 67 (20) , 575-578
Use of Outpatient Rehabilitation Among Adult Stroke Survivors — 20 States and the District of Columbia, 2013, and Four States, 2015
In 2013, approximately 31% of stroke survivors reported participation in outpatient rehabilitation for stroke after hospitalization in 20 states and the District of Columbia.
- Open Access
- 29 February 2012
- Published by IntechOpen
Inpatient Costs Associated with Ischemic Heart Disease Among Adults Aged 18-64 Years in the United States
- 29 February 2012
- Published by IntechOpen
Open AccessInpatient Costs Associated with Ischemic Heart Disease Among Adults Aged 18-64 Years in the United States
- 1 October 2010
- Vol. 16 (10) , 769-76
Costs of heart failure-related hospitalizations in patients aged 18 to 64 years.
To examine the costs of hospitalizations related to heart failure (HF) among patients aged 18 to 64 years by diagnosis status. There are few reports on HF-related hospitalization costs in patients aged 18 to 64 years, although this group has had increased HF hospitalization rates in recent decades. Using the 2005 MarketScan Commercial Claims and Encounters inpatient data set, we identified 23,216 hospitalizations for which HF was the primary or secondary diagnosis among patients aged 18 to 64 years who had a noncapitated health insurance plan. We used multivariate regression to analyze the association between patient characteristics and both hospitalization costs and length of stay (LOS). For the entire population, the mean cost of hospitalization was $23,077; the cost was higher when HF was a secondary rather than the primary diagnosis ($25,325 vs $17,654; P <.001). After controlling for covariates, hospitalizations with HF as a secondary diagnosis resulted in $3944 higher costs than those with HF as the primary diagnosis (P <.001). Among those with HF as a secondary diagnosis, the cost of hospitalization with the primary diagnosis of ischemic heart disease was $14,989 higher than it was when the primary diagnosis was noncardiovascular disease and nonrespiratory conditions (P <.001). However, patients in the latter group had a longer LOS. Information on the costs of HF-related hospitalizations can be used as inputs in economic evaluations such as cost-effectiveness analyses and as references for policy makers in making resource allocation decisions.
- 1 October 2010
- Vol. 16 (10) , 769-76
Costs of heart failure-related hospitalizations in patients aged 18 to 64 years.
To examine the costs of hospitalizations related to heart failure (HF) among patients aged 18 to 64 years by diagnosis status. There are few reports on HF-related hospitalization costs in patients aged 18 to 64 years, although this group has had increased HF hospitalization rates in recent decades. Using the 2005 MarketScan Commercial Claims and Encounters inpatient data set, we identified 23,216 hospitalizations for which HF was the primary or secondary diagnosis among patients aged 18 to 64 years who had a noncapitated health insurance plan. We used multivariate regression to analyze the association between patient characteristics and both hospitalization costs and length of stay (LOS). For the entire population, the mean cost of hospitalization was $23,077; the cost was higher when HF was a secondary rather than the primary diagnosis ($25,325 vs $17,654; P <.001). After controlling for covariates, hospitalizations with HF as a secondary diagnosis resulted in $3944 higher costs than those with HF as the primary diagnosis (P <.001). Among those with HF as a secondary diagnosis, the cost of hospitalization with the primary diagnosis of ischemic heart disease was $14,989 higher than it was when the primary diagnosis was noncardiovascular disease and nonrespiratory conditions (P <.001). However, patients in the latter group had a longer LOS. Information on the costs of HF-related hospitalizations can be used as inputs in economic evaluations such as cost-effectiveness analyses and as references for policy makers in making resource allocation decisions.